⌘K
Loading ticker…
As of 2026-08-24, Insight Molecular Diagnostics Inc. Common Stock (IMDX) has a 3-month relative strength percentile of 15 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 46. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 8.5%, relative volume 0.38×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
IMDX is in a stage 4 downtrend, week 2. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -12.1% / -19.7%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
IMDX is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $977K notional.
Held by 3 ETFs · $2M across latest filings · largest weight 0.01% (IWC).
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $977K | — |
| VXFVanguard Extended Market ETF | 0.00% | $759K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | IMDX Jan avg: -13.07% median: -13.07% win: 0% σ: 0.00% n: 1 2025-06-20 → 2026-07-31 | IMDX Feb avg: -7.82% median: -7.82% win: 0% σ: 0.00% n: 1 2025-06-20 → 2026-07-31 | IMDX Mar avg: -45.42% median: -45.42% win: 0% σ: 0.00% n: 1 2025-06-20 → 2026-07-31 | IMDX Apr avg: 22.26% median: 22.26% win: 100% σ: 0.00% n: 1 2025-06-20 → 2026-07-31 | IMDX May avg: 54.86% median: 54.86% win: 100% σ: 0.00% n: 1 2025-06-20 → 2026-07-31 | IMDX Jun avg: -4.71% median: -4.71% win: 0% σ: 0.40% n: 2 2025-06-20 → 2026-07-31 | IMDX Jul avg: -18.87% median: -18.87% win: 0% σ: 3.27% n: 2 2025-06-20 → 2026-07-31 | IMDX Aug avg: 0.40% median: 0.40% win: 100% σ: 0.00% n: 1 2025-06-20 → 2026-07-31 (current) | IMDX Sep avg: 31.23% median: 31.23% win: 100% σ: 0.00% n: 1 2025-06-20 → 2026-07-31 | IMDX Oct avg: 81.02% median: 81.02% win: 100% σ: 0.00% n: 1 2025-06-20 → 2026-07-31 | IMDX Nov avg: 2.16% median: 2.16% win: 100% σ: 0.00% n: 1 2025-06-20 → 2026-07-31 | IMDX Dec avg: 22.15% median: 22.15% win: 100% σ: 0.00% n: 1 2025-06-20 → 2026-07-31 |